Skip to content

study on Heart related ailments

Investigator-Initiated, observational, clinical assesment of Bempdoic Acid in acute coronary syndrome cases with CVD (ACL-ASCVD STUDY) - ACL-ASCVD STUDY

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/01/062146
Enrollment
200
Registered
2024-01-31
Start date
Unknown
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I708- Atherosclerosis of other arteries

Interventions

Intervention1: nil: nil Control Intervention1: nil: nil

Sponsors

TORRENT PHARMA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Male or female patients more than 18 years of age 2 Cases of ASCVD with ACS that have undergone PCI 3 Baseline LDL-C = 120 mg/dL during PCI or ?70 mg/dl for cases already receiving statin 4 Clinical cases requiring lipid goal target as less than or equal 55 mg/dl or less than equal 40 mg/dl as per ESC risk stratification for ACS and/or HeFH cases

Exclusion criteria

Exclusion criteria: 1 Hypersensitivity to the active substance or to any of the excipients. 2 Total fasting triglyceride =500 mg/dL 3 Body Mass Index (BMI) =50kg/m2 4 Gout 5 Uncontrolled Hypertension, T2DM, CSA or Heart failure 6 CKD with eGFR 7 Hepatic enzyme elevation X2 ULN 8 For women, currently pregnant (confirmed with positive pregnancy test) or breast-feeding 9 Concomitant use with simvastatin OR pravastatin

Design outcomes

Primary

MeasureTime frame
1 LDL C change in 6 Weeks in both arms 2 Responder rates for achieving LDL C less than or equal 55 or less than or equal 40 mg in 6 Weeks in both armsTimepoint: 6 weeks

Secondary

MeasureTime frame
1 Responder rates for achieving LDL C less than or equal 55 or less than or equal 40 mg at 12W in both arms 2 Proportion of participants with treatment emergent adverse event during observation period 3 Percent change in LDL C, non HDL C, Apo B, Lp a, hs CRP at 6 and 12 weeks 4 Responder rates for achieving LDL C less than or equal 55 or less than or equal 40 mg at 6 and 12 weeks for the subgroups with T2D, polyvascular disease, HeFH and High risk ASCVD {Two or more of following: Family history of; TG more than 170 mg/dl; hs-CRP more than 2 mg/dl; Smoking, Obesity, Apo B more than 130 mg/dl 5 LVD assessment for cases with polyvascular disease who have undergone CABG or Stent with or without T2D at 12 weeksTimepoint: 6 weeks and 12 weeks

Countries

India

Contacts

Public ContactDr Krishna prasad

MADRAS MEDICAL MISSION

clireco@mmm.org.in04426565961

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026